Arimidex, 1 mg 28 pcs

Arimidex is a highly selective nonsteroidal aromatase inhibitor, the enzyme by which, in postmenopausal women, androstenedione is converted in peripheral tissues to estrone and then to estradiol. Reducing circulating estradiol levels in breast cancer patients has a therapeutic effect. In postmenopausal women the drug in a daily dose of 1 mg causes a decrease in estradiol levels by 80%.

Indications

Adjuvant therapy for early hormone-positive breast cancer in postmenopausal women;
treatment of advanced breast cancer in postmenopausal women;
adjuvant therapy for early hormone-positive breast cancer in postmenopausal women after tamoxifen therapy for 2-3 years.

Pharmacological effect

Arimidex is a highly selective non-steroidal inhibitor of aromatase, an enzyme that converts androstenedione in peripheral tissues into estrone and then into estradiol in postmenopausal women. Reducing circulating estradiol levels in breast cancer patients has a therapeutic effect. In postmenopausal women, the drug at a daily dose of 1 mg causes a decrease in estradiol levels by 80%.

Special instructions

In women with estrogen receptor-negative tumors, the effectiveness of Arimidex has not been demonstrated unless there has been a previous positive clinical response to tamoxifen.

If there is doubt about the patient’s hormonal status, menopause should be confirmed by determining sex hormones in the blood serum.

There is no data on the safety of Arimidex in patients with severe liver dysfunction or in patients with severe renal failure (creatinine clearance less than 20 ml/min).

In case of persistent uterine bleeding while taking Arimidex, consultation and observation of a gynecologist is necessary.

Preparations containing estrogens should not be prescribed simultaneously with Arimidex.

By reducing circulating levels of estradiol, Arimidex may cause a decrease in bone mineral density.

In patients with osteoporosis or at risk of developing osteoporosis, bone mineral density should be assessed by densiometry (eg DEXA scan) at the beginning of treatment and over time. If necessary, treatment or prevention of osteoporosis should be started under close medical supervision.

There is no data on the simultaneous use of anastrozole and GnRH analogue drugs.

It is not known whether anastrozole improves treatment outcomes when used in conjunction with chemotherapy.

Safety data for long-term treatment with anastrozole have not yet been obtained.

When using Arimidex, ischemic diseases were observed more often than when using tamoxifen, but no statistical significance was noted.

The effectiveness and safety of Arimidex and tamoxifen when used simultaneously, regardless of the status of hormonal receptors, are comparable to those when using tamoxifen alone. The exact mechanism of this phenomenon is not yet known.

Use in pediatrics

The safety and effectiveness of the drug in children have not been established.

Impact on the ability to drive vehicles and other mechanisms that require increased concentration

Some side effects of Arimidex, such as asthenia and drowsiness, may negatively affect the ability to perform work that requires increased concentration and speed of psychomotor reactions. In this regard, it is recommended that when these symptoms appear, you should be careful when driving a car or moving machinery.

Active ingredient

Anastrozole

Composition

Active ingredients:

anastrozole 1 mg.

Excipients:

lactose monohydrate,

povidone,

sodium carboxymethylene starch,

magnesium stearate,

purified water.

Shell composition:

Macrogol 300, hypromellose, titanium dioxide, purified water.

Pregnancy

The drug is contraindicated for use during pregnancy and lactation (breastfeeding).

Contraindications

Hypersensitivity to anastrozole or other components of the drug.

Side Effects

From the reproductive system: often – dryness of the vaginal mucosa; vaginal bleeding (mainly during the first weeks after discontinuation or change of previous hormonal therapy to Arimidex®).

Interaction

Clinical drug interaction studies with antipyrine and cimetidine indicate that coadministration of Arimidex with other drugs is unlikely to result in a clinically significant interaction due to cytochrome P450.

There are no clinically significant drug interactions when taking Arimidex simultaneously with other commonly prescribed drugs.

At the moment, there is no information on the use of Arimidex in combination with other anticancer drugs.

Preparations containing estrogens should not be prescribed simultaneously with Arimidex, because they reduce the pharmacological effect of the latter.

Tamoxifen should not be prescribed simultaneously with Arimidex, as it may weaken the pharmacological effect of the latter.

Overdose

Isolated clinical cases of accidental overdose of the drug have been described.

Storage conditions

At a temperature not exceeding 30 °C

Shelf life

5 years

Manufacturer

AstraZeneca Pharmaceuticals LP, USA